Company / Capital Expenditures
Xeris Biopharma Holdings, Inc. Capital Expenditures History
FY2020-FY2021 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$1.1M
FY2021
5-year range
$1.1M / $1.1M
FY2020-FY2021
Trend
+187.8%
vs FY2020
Sector context
#112 of 194
Health Care
What the data says
At $1M, Xeris Biopharma Holdings, Inc.'s capital expenditures ranks #112 of 194 in the Health Care sector.
Based on SEC 10-K filings.
$1M in FY2021.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#112 of 194 in Health CareTop 58% of 194This company $1.1M Sector average $117.5M
▼
-99.1% below sector average
Key checks
Key Insights
- In FY2021, capital expenditures increased 187.8% year-over-year.
- Ranks #112 out of 194 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.26 (distress zone, below 1.8 threshold)
- Negative profit margin: -27.0%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | $1.1M | +187.8% |
| FY2020 | $377.0K | - |
As of FY2021 · SEC 10-K · Updated Jun 30, 2026